Drug | Tablet

Type 2 diabetes mellitus to improve glycaemic control, alone or in combination with other antidiabetic medicines along with diet and exercise

Vildagliptin is a DPP-4 inhibitor that increases incretin levels (GLP-1 and GIP), leading to glucose-dependent insulin release and reduced glucagon secretion. This lowers blood glucose with a low risk of hypoglycaemia when not used with insulin or sulfonylureas.

Take by mouth as prescribed, with or without food, usually once or twice daily depending on regimen. Continue diet and exercise; monitor blood sugar regularly. If combined with a sulfonylurea/insulin, hypoglycaemia precautions may be needed.

Headache, dizziness, tremor, nausea, diarrhea, constipation, upper respiratory tract infection, hypoglycaemia (more likely with sulfonylurea/insulin)

Not for type 1 diabetes or diabetic ketoacidosis. Monitor liver function as advised; discontinue and consult doctor if jaundice, dark urine or persistent nausea occurs. Rare risk of pancreatitis; seek medical help for severe persistent abdominal pain. Use caution in moderate to severe renal impairment and in heart failure patients as per clinician advice.

Insulin and sulfonylureas (increased hypoglycaemia risk), other antidiabetics (additive glucose-lowering), ACE inhibitors (rare increased risk of angioedema reported with DPP-4 inhibitors)

Store below 30°C in original pack, protect from moisture and heat.

Jalra 50 Tablet, Vilda 50 Tablet, Vildy 50 Tablet, Vilget 50 Tablet, Vildagliptin 50 mg Tablet (generic)